Brief: Omnicell And Fresenius Kabi Collaborate To Enhance Management Of Controlled Substances In U.S. Hospitals
10/11/2021 14:00
Nov 10 (Reuters) - Fresenius Kabi Oncology Ltd FRES.M3 :
* OMNICELL AND FRESENIUS KABI COLLABORATE TO ENHANCE
MANAGEMENT OF
CONTROLLED SUBSTANCES IN U.S. HOSPITALS
Source text for Eikon: ID:nBw7lF1cVa
Further company coverage: FRES.M3
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Omnicell
See all newsBrief: Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry As Senior Vice President
Omnicell Q1 adjusted EPS beats helped by connected devices demand, raises FY outlook
U.S. RESEARCH ROUNDUP-Amazon, Estée Lauder, Ralph Lauren
Omnicell Q4 EPS misses estimates
Omnicell Q3 adjusted EPS beats estimates, driven by connected devices and services